Slovin, S. F., Knudsen, K. E., Carbone, E., Showunmi, A., Hullings, M., Morris, M. J., … Kelly, W. K. (2016). Exploring the role of RB and AR in a phase II randomized multicenter trial of abiraterone acetate with or without cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC). In Journal of Clinical Oncology (Vol. 34, pp. TPS5093–TPS5093). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2016.34.15_suppl.tps5093

Slovin, Susan F., Karen E. Knudsen, Emily Carbone, Abosede Showunmi, Melanie Hullings, Michael J. Morris, Karen A. Autio, et al. “Exploring the role of RB and AR in a phase II randomized multicenter trial of abiraterone acetate with or without cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC).” In Journal of Clinical Oncology, 34:TPS5093–TPS5093. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.15_suppl.tps5093.

Slovin SF, Knudsen KE, Carbone E, Showunmi A, Hullings M, Morris MJ, et al. Exploring the role of RB and AR in a phase II randomized multicenter trial of abiraterone acetate with or without cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC). In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2016. p. TPS5093–TPS5093.

Slovin, Susan F., et al. “Exploring the role of RB and AR in a phase II randomized multicenter trial of abiraterone acetate with or without cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC).” Journal of Clinical Oncology, vol. 34, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2016, pp. TPS5093–TPS5093. Crossref, doi:10.1200/jco.2016.34.15_suppl.tps5093.

Slovin SF, Knudsen KE, Carbone E, Showunmi A, Hullings M, Morris MJ, Autio KA, Kampel LJ, Molina AM, Chen Y, Arauz G, Curley T, Tse K, Halabi S, Scher HI, Kelly WK. Exploring the role of RB and AR in a phase II randomized multicenter trial of abiraterone acetate with or without cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC). Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2016. p. TPS5093–TPS5093.